ETOPOSIDE AND CISPLATIN SALVAGE CHEMOTHERAPY FOR SMALL CELL LUNG-CANCER

Google Scholar
  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (4) , 369-371
Abstract
Thirty patients with previously treated small cell lung cancer received salvage combination chemotherapy with etoposide and cisplatin. Two complete and 6 partial responses were observed, for a major response rate of 27%. Responses occurred promptly and sustained palliation was achieved among responders. Myelosuppression was the major dose-limiting toxic effect. A schedule of etoposide (115 mg/m2 i.v. on Days 1-3) and cisplatin (25 mg/m2 i.v. on Days 1-3 every 28 days) is recommended for further clinical trials.